Journal article
M1 macrophage-engineered vesicles have anti-cancer activity in ovarian cancer
Cancer nanotechnology, Vol.16(1), 35
07/22/2025
DOI: 10.1186/s12645-025-00337-y
PMCID: PMC12782215
PMID: 41522833
Abstract
Background
Ovarian cancer typically presents at an advanced stage, has a poor prognosis, and is a leading cause of cancer-related deaths in women. Extracellular vesicles (EVs) are cell membrane-derived nanoparticles that function in specific cell-to-cell communication and are under development as novel drug delivery vehicles and modulators of the tumor microenvironment. Artificial cell-derived vesicles (ACDVs) from M1 macrophages are able to repolarize macrophages from a M2 to a M1 phenotype and target tumor cells in in vitro studies.
Results
In this study, we generated engineered EVs (EEVs) by membrane disruption of M1 macrophages (MEVs) with and without cisplatin to generate cisplatin-loaded MEVs (
C
-MEVs) and empty MEVs (
E
-MEVs), which we tested in an ovarian cancer mouse xenograft model.
E
-MEVs and
C
-MEVs exhibited significantly less weight loss and equivalent activity to cisplatin, with improved activity over controls.
Conclusions
Further development of MEVs for the treatment of ovarian cancer is warranted.
Details
- Title: Subtitle
- M1 macrophage-engineered vesicles have anti-cancer activity in ovarian cancer
- Creators
- Connie D. Cao - University of KentuckyJ. Robert McCorkle - University of KentuckyDerek B. Allison - University of KentuckyDonglin Yan - University of KentuckyKristen S. Hill - University of KentuckyLan Li - University of KentuckyRani Jayswal - University of KentuckyDavid Schweer - University of KentuckyCharles S. Dietrich - University of KentuckyFrederick R. Ueland - University of KentuckyChristopher I. Richards - University of KentuckyJill M. Kolesar - Markey Cancer Center, University of Kentucky, Division of Gynecologic Oncology, UK Markey Cancer Center, University of Kentucky, Department of Pharmaceutical Science and Experimental Therapeutics, University of Iowa
- Resource Type
- Journal article
- Publication Details
- Cancer nanotechnology, Vol.16(1), 35
- DOI
- 10.1186/s12645-025-00337-y
- PMID
- 41522833
- PMCID
- PMC12782215
- NLM abbreviation
- Cancer Nanotechnol
- ISSN
- 1868-6958
- eISSN
- 1868-6966
- Publisher
- Springer Vienna
- Grant note
- T32 CA160003 / NCI 30481152221; 30481152221 / Kentucky Network for Innovation & Commercial Grant
- Language
- English
- Date published
- 07/22/2025
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics; Obstetrics and Gynecology
- Record Identifier
- 9984865444102771
Metrics
56 Record Views